[1] |
XU Wenhao, TIAN Xi, Aihetaimujiang·Anwaier , QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei.
A systematic review of current advancements of artificial intelligence in genitourinary cancers
[J]. China Oncology, 2022, 32(1): 68-74.
|
[2] |
WEI Yu , ZHANG Tingwei , HE Yi , LI Jun , BI Jianbin , ZENG Yu , WAN Lijun , WU Gaoliang , WANG Huansheng , ZHANG Jun , ZHU Wei , QU Yuanyuan , ZHU Yao , YE Dingwei .
Preliminary study on efficacy and safety of fluzoparib in patients with metastatic castration-resistant prostate cancer
[J]. China Oncology, 2021, 31(7): 561-566.
|
[3] |
CAO Dalong, ZHU Wenkai, SHI Guohai, ZHANG Hailiang, WANG Ziliang, YE Dingwei.
The influence of PRUNE2 gene point mutation on proliferation, apoptosis, invasion and migration of prostate cancer DU145 cells
[J]. China Oncology, 2021, 31(6): 441-446.
|
[4] |
WANG Zhu, ZHANG Ying, ZHANG Jianwen, DENG Qiong, LIANG Hui.
Nuclear receptor HNF4α promotes castration-resistant prostate cancer via its regulation of androgen receptor expression
[J]. China Oncology, 2021, 31(3): 170-175.
|
[5] |
BIAN Xiaojie, YE Dingwei.
New ideas of androgen deprivation therapy for prostate cancer: new progress in clinical research of testosterone maximum control
[J]. China Oncology, 2021, 31(12): 1209-1214.
|
[6] |
PAN Jian, WEI Yu, YE Dingwei, ZHU Yao.
Correlation between EGFR (rs884419) gene polymorphism and clinicopathological characteristics of prostate cancer
[J]. China Oncology, 2021, 31(11): 1104-1109.
|
[7] |
PAN Jian, WEI Yu, WU Junlong, WAN Fangning, YE Dingwei, ZHU Yao.
Correlation of HSD3B1 gene polymorphism and clinicopathological characteristics of prostate cancer
[J]. China Oncology, 2020, 30(9): 650-655.
|
[8] |
FAN Bo , QI Pan , SU Jianzhi , WEI Shufei , ZHANG Xuan , ZHANG Aili .
Baseline characteristics and survival analysis of patients with prostate cancer in the Fourth Hospital of Hebei Medical University
[J]. China Oncology, 2020, 30(8): 620-625.
|
[9] |
China Anti-Cancer Association Genitourinary Cancer Committee, Chinese Society of Clinical Oncology Committee on Prostate Cancer.
Chinese expert consensus on genomic testing of prostate cancer patients (the 2020 edition)
[J]. China Oncology, 2020, 30(7): 551-560.
|
[10] |
XU Yaozong , GU Xiao , WANG Fei , LUAN Yang , LU Shengming , HUANG Tianbao , DING Xuefei .
Clinical features of prostate cancer patients with Gleason score 8-10 and low preoperative PSA level
[J]. China Oncology, 2020, 30(5): 383-387.
|
[11] |
LI Zeng, LIAO Hong, MAO Dun, WU Yi, XIAO Yingming, YANG Shengke, ZHONG Lei, ZHOU Shukui, CHEN Yongji.
The value of 18 F-PSMA-1007 PET/CT in accurate assessment of newly diagnosed prostate cancer and its impact on clinical treatment decisions
[J]. China Oncology, 2020, 30(3): 231-236.
|
[12] |
ZHOU Jian, ZHANG Chaoyang, SUN Wei, YANG Jun, ZHANG Zhichao, QI Xiaohong.
Effects of miR-503 targeting TLR4 on drug resistance to docetaxel in prostate cancer
[J]. China Oncology, 2020, 30(11): 858-864.
|
[13] |
KANG Xun,ZHANG Xiyou,CHEN Feng,LI Dandan,DONG Qianqian,SONG Qingkun,ZHONG Xiaosong,LI Wenbin .
The toxicity of chimeric antigen receptor T-cell immunotherapy in B-cell lymphoma: a Meta-analysis
[J]. China Oncology, 2019, 29(8): 568-575.
|
[14] |
YANG Qing, OU Xiaomin, HU Chaosu.
Prognostic significance of platelet-to-lymphocyte ratio in patients with nasopharyngeal carcinoma: a Meta-analysis
[J]. China Oncology, 2019, 29(8): 576-582.
|
[15] |
CHEN Yang,YANG Qingsong,LU Jianping .
Differentiation of central gland prostate cancer from benign prostatic hyperplasia by using monoexponential and biexponential DWI models
[J]. China Oncology, 2019, 29(8): 583-589.
|